• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

异山梨醇二硝酸酯和异山梨醇单硝酸酯在人体中的口服吸收与处置

Oral absorption and disposition of isosorbide dinitrate and isosorbide mononitrates in man.

作者信息

Laufen H, Aumann M, Leitold M

出版信息

Arzneimittelforschung. 1983;33(7):980-4.

PMID:6684933
Abstract

The plasma concentrations of isosorbide dinitrate (ISDN) and its two pharmacologically active metabolites isosorbide 2-mononitrate (IS-2-MN) and isosorbide 5-mononitrate (IS-5-MN) were determined after oral administration of 20 mg ISDN and 20 mg of each of the mononitrates. The mean concentration-time curve of ISDN showed a peak of 51.6 ng/ml 15 min after drug intake, and declined bi-exponentially with a terminal half-life of 36.5 min. The mean concentrations of the simultaneously measured metabolic products IS-2-MN and IS-5-MN reached a maximum of 40.5 ng/ml and 144.4 ng/ml, respectively. In contrast, after the direct ingestion of isosorbide mononitrates, peaks of 409.1 ng/ml (IS-2-MN) and 483.2 ng/ml (IS-5-MN) were observed in the corresponding mean curves. Mean half-lives of 1.72 h for IS-2-MN and 4.20 h for IS-5-MN were calculated. The mean apparent volumes of distribution were 44.5 l (IS-2-MN) and 34.4 l (IS-5-MN), suggesting that the isosorbide mononitrates are distributed throughout the whole body fluid. After ISDN administration, it was estimated that 3.0 mg IS-2-MN and 7.8 mg IS-5-MN reached the systemic circulation. This corresponds to 63% of the ISDN dose being converted to isosorbide mononitrates by metabolic processes.

摘要

口服20毫克硝酸异山梨酯(ISDN)以及20毫克每种单硝酸酯后,测定了血浆中硝酸异山梨酯(ISDN)及其两种药理活性代谢物2-单硝酸异山梨酯(IS-2-MN)和5-单硝酸异山梨酯(IS-5-MN)的浓度。ISDN的平均浓度-时间曲线显示,服药后15分钟出现峰值51.6纳克/毫升,并呈双指数下降,终末半衰期为36.5分钟。同时测定的代谢产物IS-2-MN和IS-5-MN的平均浓度分别达到最大值40.5纳克/毫升和144.4纳克/毫升。相比之下,直接摄入单硝酸异山梨酯后,相应的平均曲线中观察到IS-2-MN的峰值为409.1纳克/毫升,IS-5-MN的峰值为483.2纳克/毫升。计算得出IS-2-MN的平均半衰期为1.72小时,IS-5-MN的平均半衰期为4.20小时。IS-2-MN的平均表观分布容积为44.5升,IS-5-MN的平均表观分布容积为34.4升,这表明单硝酸异山梨酯分布于全身体液中。服用ISDN后,估计有3.0毫克IS-2-MN和7.8毫克IS-5-MN进入体循环。这相当于ISDN剂量的63%通过代谢过程转化为单硝酸异山梨酯。

相似文献

1
Oral absorption and disposition of isosorbide dinitrate and isosorbide mononitrates in man.异山梨醇二硝酸酯和异山梨醇单硝酸酯在人体中的口服吸收与处置
Arzneimittelforschung. 1983;33(7):980-4.
2
Pharmacokinetics of isosorbide dinitrate and isosorbide-5-mononitrate.硝酸异山梨酯和5-单硝酸异山梨酯的药代动力学。
Int J Clin Pharmacol Ther Toxicol. 1989 Sep;27(9):445-53.
3
[Concentration-time profile of isosorbide dinitrate and its metabolites in plasma following percutaneous resorption of a transdermal therapeutic system].
Arzneimittelforschung. 1987 Nov;37(11):1301-3.
4
Isosorbide 5-mononitrate and isosorbide 2-mononitrate kinetics after intravenous and oral dosing.静脉注射和口服给药后5-单硝酸异山梨酯和2-单硝酸异山梨酯的动力学
Clin Pharmacol Ther. 1984 Oct;36(4):485-92. doi: 10.1038/clpt.1984.208.
5
Isosorbide dinitrate bioavailability, kinetics, and metabolism.硝酸异山梨酯的生物利用度、动力学及代谢。
Clin Pharmacol Ther. 1985 Aug;38(2):140-9. doi: 10.1038/clpt.1985.150.
6
Pharmacokinetics and metabolism of isosorbide-dinitrate after intravenous and oral administration.静脉注射和口服后异山梨醇二硝酸酯的药代动力学及代谢
Eur J Clin Pharmacol. 1985;27(6):637-44. doi: 10.1007/BF00547041.
7
[Comparative pharmacokinetics and bioavailability of isosorbide dinitrate and its metabolites isosorbide 5- and 2-mononitrate from delayed-release preparations].[硝酸异山梨酯及其代谢产物5-单硝酸异山梨酯和2-单硝酸异山梨酯缓释制剂的比较药代动力学和生物利用度]
Arzneimittelforschung. 1982;32(9):1138-40.
8
Bioavailability of isosorbide dinitrate and its two mononitrate metabolites from sustained-release formulations.硝酸异山梨酯及其两种单硝酸代谢产物在缓释制剂中的生物利用度。
Int J Clin Pharmacol Ther Toxicol. 1983 Oct;21(10):514-8.
9
Pharmacokinetics of isosorbide dinitrate and its mononitrate metabolites after intravenous infusion.静脉输注后硝酸异山梨酯及其单硝酸代谢产物的药代动力学
J Pharmacokinet Biopharm. 1986 Feb;14(1):1-17. doi: 10.1007/BF01059280.
10
Pharmacokinetics of intravenous isosorbide-dinitrate.静脉注射硝酸异山梨酯的药代动力学
J Pharmacokinet Biopharm. 1982 Dec;10(6):575-86. doi: 10.1007/BF01062541.

引用本文的文献

1
Isosorbide-5-nitrate sustained-release pellets - an example of computer-supported drug development.硝酸异山梨酯控释微丸——计算机支持药物开发的范例。
Pharm Res. 1985 Jan;2(1):30-6. doi: 10.1023/A:1016314005874.
2
The role of metabolites in bioequivalency assessment. III. Highly variable drugs with linear kinetics and first-pass effect.代谢物在生物等效性评估中的作用。III. 具有线性动力学和首过效应的高可变药物。
Pharm Res. 2000 Nov;17(11):1432-6. doi: 10.1023/a:1007581016352.
3
Response to changing plasma concentrations of isosorbide-bound NO2 during acute and sustained treatment with isosorbide dinitrate in patients with coronary artery disease.
冠心病患者在急性和持续应用硝酸异山梨酯治疗期间,对与异山梨酯结合的NO2血浆浓度变化的反应。
Clin Cardiol. 2000 Jun;23(6):427-32. doi: 10.1002/clc.4960230610.
4
The effect of food on the oral absorption of isosorbide-5-mononitrate.食物对单硝酸异山梨酯口服吸收的影响。
Br J Clin Pharmacol. 1984 Dec;18(6):967-8. doi: 10.1111/j.1365-2125.1984.tb02574.x.
5
Pharmacokinetics of isosorbide dinitrate and its mononitrate metabolites after intravenous infusion.静脉输注后硝酸异山梨酯及其单硝酸代谢产物的药代动力学
J Pharmacokinet Biopharm. 1986 Feb;14(1):1-17. doi: 10.1007/BF01059280.
6
Pharmacokinetics of isosorbide-5-nitrate in renal failure.
Eur J Clin Pharmacol. 1986;30(3):349-50. doi: 10.1007/BF00541542.
7
Isosorbide dinitrate in plasma and dialysate during haemodialysis.
Eur J Clin Pharmacol. 1986;30(2):187-90. doi: 10.1007/BF00614300.
8
Pharmacokinetics of isosorbide-5-nitrate during haemodialysis and peritoneal dialysis.
Eur J Clin Pharmacol. 1987;32(5):503-5. doi: 10.1007/BF00637678.
9
Pharmacokinetics of oral glycerol-1-nitrate.口服硝酸甘油-1的药代动力学。
Eur J Clin Pharmacol. 1986;31(2):169-75. doi: 10.1007/BF00606654.